These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35061210)

  • 1. High-risk pituitary adenomas and strategies for predicting response to treatment.
    Kontogeorgos G; Thodou E; Osamura RY; Lloyd RV
    Hormones (Athens); 2022 Mar; 21(1):1-14. PubMed ID: 35061210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delineating the Spectrum of Pituitary Adenoma Based on the WHO 2017 Classification.
    Paramita P; Shilpa R; Nandeesh BN; Yasha TC; Vani S
    Neurol India; 2024 Jan; 72(1):96-101. PubMed ID: 38443009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the 2017 WHO Classification of Pituitary Tumors.
    Mete O; Lopes MB
    Endocr Pathol; 2017 Sep; 28(3):228-243. PubMed ID: 28766057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silent pituitary plurihormonal adenoma: clinical relevance of immunohistochemical analysis.
    García-Sáenz M; Uribe-Cortés D; González-Virla B; Mendoza-Zubieta V; Vargas-Ortega G
    Rev Med Inst Mex Seguro Soc; 2019 Apr; 57(1):48-55. PubMed ID: 31071255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2017 WHO classification of pituitary adenoma: overview and comments.
    Inoshita N; Nishioka H
    Brain Tumor Pathol; 2018 Apr; 35(2):51-56. PubMed ID: 29687298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological analysis of 250 cases of pituitary adenoma under the new WHO classification.
    Liu J; He Y; Zhang X; Yan X; Huang Y
    Oncol Lett; 2020 Mar; 19(3):1890-1898. PubMed ID: 32194684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
    Lenders N; McCormack A
    Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
    Salehi F; Scheithauer BW; Kros JM; Lau Q; Fealey M; Erickson D; Kovacs K; Horvath E; Lloyd RV
    J Neurooncol; 2011 Sep; 104(3):647-57. PubMed ID: 21311951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
    Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
    Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
    Lau Q; Scheithauer B; Kovacs K; Horvath E; Syro LV; Lloyd R
    Pituitary; 2010 Dec; 13(4):367-79. PubMed ID: 20740317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.
    Gomez-Hernandez K; Ezzat S; Asa SL; Mete Ö
    Turk Patoloji Derg; 2015; 31 Suppl 1():4-17. PubMed ID: 26177314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms.
    Inomoto C; Tahara S; Oyama K; Kimura M; Matsuno A; Teramoto A; Osamura RY
    Brain Tumor Pathol; 2021 Jul; 38(3):183-188. PubMed ID: 34269950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory Pit1 plurihormonal tumours and thyrotroph adenomas.
    Nf L; Ai M
    Pituitary; 2023 Apr; 26(2):182-186. PubMed ID: 37117845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
    Salehi F; Scheithauer BW; Kovacs K; Horvath E; Syro LV; Sharma S; Manoranjan B; Cusimano M
    Neurosurgery; 2012 Feb; 70(2):491-6; discussion 496. PubMed ID: 21822153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.
    Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T
    Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
    Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
    Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rab3B immunoexpression in human pituitary adenomas.
    Rotondo F; Scheithauer BW; Kovacs K; Bell DC
    Appl Immunohistochem Mol Morphol; 2009 May; 17(3):185-8. PubMed ID: 19384079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors.
    Saeger W; Koch A
    Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):146-156. PubMed ID: 33690870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
    Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
    Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.